In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Apr 23

PMID 35455402

Authors

Muanpetch Rachayon

Ketsupar Jirakran

Pimpayao Sodsai

Siriwan Klinchanhom

Atapol Sughondhabirom

Kitiporn Plaimas

Apichat Suratanee

Michael Maes

Affiliations

Soon will be listed here.

Abstract

Major depressive disorder and major depressive episodes (MDD/MDE) are characterized by the activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS). Cannabidiol (CBD) is a phytocannabinoid isolated from the cannabis plant, which is reported to have antidepressant-like and anti-inflammatory effects. The aim of the present study is to examine the effects of CBD on IRS, CIRS, M1, T helper (Th)-1, Th-2, Th-17, T regulatory (Treg) profiles, and growth factors in depression and healthy controls. Culture supernatant of stimulated (5 μg/mL of PHA and 25 μg/mL of LPS) whole blood of 30 depressed patients and 20 controls was assayed for cytokines using the LUMINEX assay. The effects of three CBD concentrations (0.1 µg/mL, 1 µg/mL, and 10 µg/mL) were examined. Depression was characterized by significantly increased PHA + LPS-stimulated Th-1, Th-2, Th-17, Treg, IRS, CIRS, and neurotoxicity profiles. CBD 0.1 µg/mL did not have any immune effects. CBD 1.0 µg/mL decreased CIRS activities but increased growth factor production, while CBD 10.0 µg/mL suppressed Th-1, Th-17, IRS, CIRS, and a neurotoxicity profile and enhanced T cell growth and growth factor production. CBD 1.0 to 10.0 µg/mL dose-dependently decreased sIL-1RA, IL-8, IL-9, IL-10, IL-13, CCL11, G-CSF, IFN-γ, CCL2, CCL4, and CCL5, and increased IL-1β, IL-4, IL-15, IL-17, GM-CSF, TNF-α, FGF, and VEGF. In summary, in this experiment, there was no beneficial effect of CBD on the activated immune profile of depression and higher CBD concentrations can worsen inflammatory processes.

Citing Articles

Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.

Engeli B, Lachenmeier D, Diel P, Guth S, Villar Fernandez M, Roth A Nutrients. 2025; 17(3).

PMID: 39940347 PMC: 11820564. DOI: 10.3390/nu17030489.

In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.

Maes M, Almulla A, Zhou B, Algon A, Sodsai P Sci Rep. 2024; 14(1):7344.

PMID: 38538641 PMC: 10973347. DOI: 10.1038/s41598-024-57350-1.

T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors.

Almulla A, Algon A, Tunvirachaisakul C, Al-Hakeim H, Maes M J Adv Res. 2023; 64:171-181.

PMID: 37967811 PMC: 11464466. DOI: 10.1016/j.jare.2023.11.012.

Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles.

Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Debnath M Cells. 2022; 11(9).

PMID: 35563878 PMC: 9105661. DOI: 10.3390/cells11091564.

Cannabidiolic acid in Hemp Seed Oil Table Spoon and Beyond.

Nigro E, Pecoraro M, Formato M, Piccolella S, Ragucci S, Mallardo M Molecules. 2022; 27(8).

PMID: 35458762 PMC: 9029873. DOI: 10.3390/molecules27082566.

References

Oglodek E, Szota A, Just M, Mos D, Araszkiewicz A . Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. Pharmacol Rep. 2014; 66(5):920-6. DOI: 10.1016/j.pharep.2014.06.001. View

Maes M . A review on citation amnesia in depression and inflammation research. Neuro Endocrinol Lett. 2015; 36(1):1-6. View

Burstein S . Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015; 23(7):1377-85. DOI: 10.1016/j.bmc.2015.01.059. View

Leonard B, Maes M . Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2011; 36(2):764-85. DOI: 10.1016/j.neubiorev.2011.12.005. View

Sheng W, Hu S, Min X, Cabral G, Lokensgard J, Peterson P . Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2004; 49(2):211-9. DOI: 10.1002/glia.20108. View

Cohen E, Margalit I, Shochat T, Goldberg E, Krause I . Markers of Chronic Inflammation in Overweight and Obese Individuals and the Role of Gender: A Cross-Sectional Study of a Large Cohort. J Inflamm Res. 2021; 14:567-573. PMC: 7920597. DOI: 10.2147/JIR.S294368. View

Millar S, Stone N, Bellman Z, Yates A, England T, OSullivan S . A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019; 85(9):1888-1900. PMC: 6710502. DOI: 10.1111/bcp.14038. View

Zimmerman M, Martinez J, Young D, Chelminski I, Dalrymple K . Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013; 150(2):384-8. DOI: 10.1016/j.jad.2013.04.028. View

Kaplan B, Springs A, Kaminski N . The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol. 2008; 76(6):726-37. PMC: 2748879. DOI: 10.1016/j.bcp.2008.06.022. View

10.

Leighton S, Nerurkar L, Krishnadas R, Johnman C, Graham G, Cavanagh J . Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2017; 23(1):48-58. PMC: 5754468. DOI: 10.1038/mp.2017.205. View

11.

Anil S, Shalev N, Vinayaka A, Nadarajan S, Namdar D, Belausov E . Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 2021; 11(1):1462. PMC: 7809280. DOI: 10.1038/s41598-021-81049-2. View

12.

Daria S, Proma M, Shahriar M, Islam S, Bhuiyan M, Islam M . Serum interferon-gamma level is associated with drug-naïve major depressive disorder. SAGE Open Med. 2020; 8:2050312120974169. PMC: 7682211. DOI: 10.1177/2050312120974169. View

13.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

14.

Dahl J, Ormstad H, Aass H, Malt U, Traskman Bendz L, Sandvik L . The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014; 45:77-86. DOI: 10.1016/j.psyneuen.2014.03.019. View

15.

Zoppi S, Perez Nievas B, Madrigal J, Manzanares J, Leza J, Garcia-Bueno B . Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology. 2010; 36(4):805-18. PMC: 3055736. DOI: 10.1038/npp.2010.214. View

16.

Kahl K, Kruse N, Faller H, Weiss H, Rieckmann P . Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology. 2002; 27(6):671-81. DOI: 10.1016/s0306-4530(01)00068-3. View

17.

Zgair A, Lee J, Wong J, Taha D, Aram J, Di Virgilio D . Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017; 7(1):14542. PMC: 5674070. DOI: 10.1038/s41598-017-15026-z. View

18.

Chiurchiu V, Cencioni M, Bisicchia E, De Bardi M, Gasperini C, Borsellino G . Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol. 2013; 73(5):626-36. DOI: 10.1002/ana.23875. View

19.

Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S . Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(3):658-63. DOI: 10.1016/j.pnpbp.2006.12.011. View

20.

Borges R, Batista Jr J, Viana R, Baetas A, Orestes E, Andrade M . Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules. 2013; 18(10):12663-74. PMC: 6269679. DOI: 10.3390/molecules181012663. View